Truist Raises Cigna (CI) Price Target to $350, Sees Clearer Growth Outlook after Q4

The Cigna Group (NYSE:CI) is included among the 13 Best Strong Buy Dividend Stocks to Invest in.

On February 17, Truist raised its price recommendation on The Cigna Group (NYSE:CI) to $350 from $320. The firm reiterated a Buy rating on the stock. The analyst updated the firm’s model following the company’s Q4 results and its initial outlook for 2026, pointing to improved visibility into the business trajectory.

David Cordani, the company’s CEO and Chair, said The Cigna Group delivered adjusted revenue of $275 billion for the full year, marking an 11% increase. He also noted that adjusted earnings per share came in at $29.84, up 9% compared with the previous year, reflecting steady underlying growth.

He added that the company continued to reposition its portfolio through a series of strategic moves. These included increasing its investment in Shields Health Solutions and completing the divestiture of Cigna Healthcare’s Medicare business. Cordani also said the company had resolved its Federal Trade Commission matters through a broad settlement tied to its pharmacy benefits operations. He stated that the agreement is expected to deliver “$7 billion in out-of-pocket cost relief over the next 10 years for the 100 million customers and patients we serve.”

Cordani also pointed to the launch of a rebate-free pharmacy benefit model. The initiative was first developed in early 2025 and formally introduced in the third quarter. He said the model “enhances the value we provide to customers and clients, all while we continue to strengthen our position and deliver on our long-term shareholder commitments.”

The Cigna Group operates as a global health company, with its business anchored around two main growth platforms: Evernorth Health Services and Cigna Healthcare.

READ NEXT: 13 Best NASDAQ Dividend Stocks to Buy Now and 14 Best Warren Buffett Dividend Stocks to Buy

Disclosure: None.